ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

Hatch Introduces Bill to Modify Delaney Amendment

June 13, 1986

In Brief: Last Bit of Nonsense By Weinberger; Magnuson May Write NCI Positions Into HEW Money Bill

July 18, 1975

Fellowships In Japan Available Through NIH

October 13, 1995

Also In This 12-page Issue: NCI To Cut Budgets For New Grants By 29 Percent. R01s To Be Funded At 11th Percentile.

February 3, 2006

Univ. Of Pittsburgh Plans Molecular Medicine Institute.

January 25, 2002